Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
British journal of pharmacology
Date
2026-07-01
Source
PubMed
DOI
10.1111/bph.70138
PubMed
40726049

Authors

Qureshi OCowley JPegg ACooper AJGordon JBrady CABelli AButterworth SUpthegrove RAndrews NBarnes NM
Watch author

Derived topics and classifications

psilocybin Receptor PharmacologyAnimal StudyInflammationImmune Function Other

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?2026-07-01Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe AnxietyDrugs and Drug Candidates · 2026-08-12Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-08-12Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.Frontiers in systems neuroscience · 2025-01-01Repeat Dosing of Psilocybin in Headache DisordersClinicalTrials.gov · 2024-02-09Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study IIClinicalTrials.gov · 2023-10-12NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.ClinicalTrials.gov · 2022-11-16